SPECIAL NOTICE
A -- Vaxfectin (TVDV) Study
- Notice Date
- 8/10/2009
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, NMLC, 693 Neiman Street, FT Detrick, Maryland, 21702-9203, United States
- ZIP Code
- 21702-9203
- Solicitation Number
- N3239809RCCV006
- Archive Date
- 9/4/2009
- Point of Contact
- Douglas J Nathan, Phone: 3016191131
- E-Mail Address
-
douglas.nathan@med.navy.mil
(douglas.nathan@med.navy.mil)
- Small Business Set-Aside
- N/A
- Description
- GLP TOXICITY STUDY FOR Vaxfectin (TVDV) VACCINE The contractor will perform a GLP toxicity study in New Zealand White rabbits as described below. The following requirements must be met: 1. The contractor must have a facility size that can accommodate up to 52 rabbits at one time. 2. The contractor must have experience with GLP toxicity studies to support Investigational New Drug submissions to the FDA. 3. The contractor must be an “Assured Institution” by the National Institute of Health Office of Lab Animal Welfare (OLAW) and be certified by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). 4. The contractor must be able to initiate the study by 1 October 2009 and earlier starts are preferable. Proposed starting dates must accompany the proposal. 5. The study performance site must be within reasonable driving distance of the NMRC facility to allow easy coordination, training, and movement of the vaccine test articles from the WRAIR GMP storage site. 6. The contractor will provide weekly updates to the principle investigator at NMRC on the interim results of the study. Such information includes graphs, charts and direct communication by phone and email. The contractor will provide an audited report within 12 weeks of study conclusion. The study report will include a summary and detailed charts, figures and supporting information to report on the elements described below. 7. The contractor will submit a bid to conduct the required toxicity study (group 1, 2, and 3) in Figure 1 and will also submit a bid to conduct the optional study (group 4) in Figure 2. Toxicity Study: Test articles: supplied as single dose kits, designed as single vial Group 1, three vials Group 2, two vials Group 3, and two vials Group 4, storage at -30 °C. Formulation SOPs and on-site training (or training video) to be provided by sponsor, however in brief multi-vial kits require 5 min vortex step (hands-free) and should take ~10 min to complete. •Species: New Zealand White rabbits, 3.0-3.5 kg. •Groups and dosing: oGroup 1: PBS (two 1 mL doses bilateral IM) for a total dose of 2 ml per immunization; and oGroup 2: TVDV (two 1 ml doses bilateral IM) for a total dose of 2 ml per immunization. oGroup 3: Vaxfectin (1 ml dose unilateral IM) for a total dose of 1 ml one time. oGroup 4: TVDV without vaxfectin or misformulation (two 1 ml doses bilateral IM) for a total dose of 2 ml per immunization. •Group size: Group 1: PBS at N=12 (equally divided between sexes); Group 2: TVDV at N=16 (equally divided between sexes); Group 3: Vaxfectin at N=12 (equally divided between sexes); Group 4: TVDV without Vaxfectin at N= 12. •Dosing schedule: Groups 1, 2 and 4 days 0, 30, 60 and 90. Group 3 day 0. •Scheduled euthanasia time-points: Groups 1, 2 and 4 50% of animals on D92 (acute toxicity animals), 50% on D120 (recovery animals). Group 3 50% of animals on D2 (acute toxicity animals), 50% on D30 (recovery animals) •Endpoints: oMortality oClinical pathology with hematology/coagulation/clinical chemistry: standard panels plus C-reactive protein and fibrinogen (see Figure 1): pre-dose and Days 2, 30 (pre-dose (pre-euthanasia Group 3)), 60 (pre-dose), 90 (pre-dose), 92, and 120. Serum sample to be returned frozen to sponsor for assays after each blood draw. Provide reference values for clinical chemistry endpoints based on the historical experience at your laboratory. The reference values should include the average value and standard deviations or 75% quartiles values. oClinical observations: pre-study and weekly thereafter oFood consumption: pre-study and daily oWeight: pre-study, 48 hours post each injection, weekly on study and at euthanasia oBody Temperature: pre-study, 24 hours post injection, weekly on study and at euthanasia. oOphthalmological exams: pre-study and prior to scheduled euthanasia (up to 48 hr prior) oDermal observations (Draize scoring): pre-study and daily after vaccination until normal (assume 5 days for estimating purposes). Report eschar, abscess, and other non-draize measured abnormalities in a manner consistent with FDA recommendations. oGross pathology with organ weights and ratio and full histopathology at scheduled euthanasia. BM smear to be prepared at take-downs for subsequent evaluations if warranted (pending histopathology report). (Contact primary point of contact for tables that would not copy into this announcement properly)
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DON/BUMED/N62645/N3239809RCCV006/listing.html)
- Place of Performance
- Address: Within Commuting distance of the below address as stated in #5 above., 503 Robert Grant Ave, Rockville, Maryland, 20910, United States
- Zip Code: 20910
- Zip Code: 20910
- Record
- SN01905784-W 20090812/090811001138-e728c28d479cbb5547c9deb3b93f53c8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |